Cancer Vaccines
Cancer Vaccines | 18-19 Sept 2013, London UK
Manipulating Tumour Immunogenicity to be addressed at Cancer Vaccines Summit | 18-19 September, London UK
I am pleased to be taking part in Cancer Vaccines, which will highlight important advances both from the academic and industry viewpoints.
LONDON, UNITED KINGDOM, July 31, 2013 /EINPresswire.com/ -- New Speaker Announcement:— Prof. Graham Pawelec, University of Tübingen
SMi are pleased to announce that Dr Mark Cobbold, Senior Clinical Research Fellow at the University of Birmingham, will be presenting at the 2nd annual Cancer Vaccines conference this September.
Attendees at this year’s event will receive a unique insight into manipulating tumour immunogenicity. The presentation on: Manipulating Tumour Immunogenicity in vivo: New Tools for Old Targets, will highlight the following area’s:
• New technology to alter the immunogenicity of a tumour in vivo.
• Manipulation by the delivery of antigens at the tumour site.
• The engagement of pre-existing immunity with tumours - novel mechanism for immunotherapy
• Analogous to effective conjugate vaccines
Click here for full speaker line up.
An ideal platform for learning about the new advances in cancer vaccines , the 2nd annual event will present attendees with latest developments and innovations in this ever changing field.
Key Benefits of Attending:
• Explore T cell receptor mediated cytotoxicity in cancer cell lines with a detailed presentation from Christoph Lampert, Roche.
• Evaluate key regulatory issues from a keynote address with Alex Kudrin, Medical Assessor, Biological Licensing, MHRA
• Participate in the interactive pre-conference workshop on Combination Therapies with Immunotherapeutics led by Transgene
• Hear about the most advanced Phase III trials in Lung Cancer
• Consider the potential long term implications of inducing an anti-tumour immune response
Cancer Vaccines | 18-19 September, London UK
For further details visit the event website at www.cancervaccinesevent.com
Teri Arri
SMi Group
+44 (0)20 7827 6162
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
